Antihistamines
Özet
Antihistamines are among the most commonly prescribed drugs for skin diseases. H1 antihistamines, which are mainly used in skin and allergic diseases, can be classified as first generation (less H1 receptor selectivity) and second generation (more H1 receptor selectivity) groups. Second generation H1 antihistamines are less lipophilic, have a lower risk of crossing the blood-brain barrier, and have fewer side effects and drug interactions. However, physiological changes and possible comorbidities in the elderly may negatively affect the pharmacokinetics and pharmacodynamics of the drug. In addition, polypharmacy, one of the most common problems among the elderly, is a serious problem today. The use of second- generation antihistamines is recommended for the elderly due to the low drug interactions and side effects. At the same time, comorbidities and medications used should be examined comprehensively, and the safest possible approach should be preferred.
Referanslar
Yosipovitch G, Greaves MW, Schmelz M. Itch. The Lancet. 2003;361(9358):690-694. doi:10.1016/S0140-6736(03)12570-6
Potenzieri C, Undem BJ. Basic mechanisms of itch. Clin Exp Allergy. 2012;42(1):8-19. doi:10.1111/j.1365-2222.2011.03791.x
Alikahn A, Hocker T. Review of Dermatology. Elsevier; 2017.
Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain. 2008; 4:29. [PubMed: 18667087].
Shirley DW, Sterrett J, Haga N, Durham C. The therapeutic versatility of antihistamines: A comprehensive review. Nurse Pract. 2020;45(2):8-21. doi:10.1097/01.NPR.0000651112.76528.ed
Davies MG, Greaves MW. Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol. 1980; 9:461–465. [PubMed: 6446929].
Cataldi M, Borriello F, Granata F, Annunziato L, Marone G. Histamine Receptors and Antihistamines: From Discovery to Clinical Applications. In: Bergmann KC, Ring J, eds. Chemical Immunology and Allergy. Vol 100. S. Karger AG; 2014:214-226. doi:10.1159/000358740
Takahashi H, Ishida-Yamamoto A, Iizuka H: Effects of bepotastine, cetirizine, fexofenadine and olopatidine on histamine induced whealand flare-response, sedation and psychomotor performance. Exp Dermatol 2004;29:526532.
Greaves MW. Antihistamines in Dermatology. Skin Pharmacol Physiol. 2005;18(5):220-229. doi:10.1159/000086667
Hansen J, Klimek L, H+Ârmann K. Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines. Drugs Aging 2005; 22(4):289-296.
Dávila I, Montoro J, Sastre J, Valero A. Use of Second Generation H1 Antihistamines in Special Situations. J Investig Allergol Clin Immunol. 2013;23.
Hutchison LC, Sleeper RB. Fundamentals of Geriatric Pharmacotherapy: An Evidence-Based Approach. Bethesda (MD): American Society of Health-System Pharmacists; 2010.
Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80:388-393.
Grinnell M, Price KN, Shah A, Butler DC. Antihistamine safety in older adult dermatologic patients. J Am Acad Dermatol. 2022;87(2):381-386. doi:10.1016/j.jaad.2021.01.027
Masoudi FA, Baille CA, Wang Y, et al. The complexity and cost of drug regimens of aging patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005; 165(18):2069-2076.
Gray S, Anderson M, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407.
Rudolph J, Salow M, Angelini M. The Anticholinergic Risk Scale and anticholinergic adverse effects in aging persons. Arch Intern Med. 2008;168(5):508-513.
Agostini J, Leo-Summers L, Inouye S. Cognitive and other adverse effects of diphenhydramine use in hospitalized aging patients. Arch Intern Med. 2001;161(17):2091-2097.
Cho H, Myung J, Suh HS, Kang HY. Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporos Int. 2018;29:2163-2170.
Barta J, Valero A, Cuvillo A, et al. Interactions of the H1 antihistamines. JInvestigAllergolClinImmunol. 2006;16(1):29-36.
Philpot E. Safety of second generation antihistamines. Allergy Asthma Proc. 2000;21(1):15-20.
Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004; 18(4):399-411.
Lippert C, Rao N, Eller M, Weir S. Pharmacokinetics of fexofenadine in liver diseased patients. Pharm Res. 1996;13 (Suppl), 431.
Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol. 1999; 83(10):1451-1454.
Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol. 2012;35(Suppl 1):18-24.
Sologuren A, Lucero ML, Valiente R, Charles H, Mail S.J. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol. 105[Suppl 1], 106-107. 2009.
Church MK. Safety and efficacy of bilastine: a new H(1)antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011; 10(5):779-793.
Henz BM. The pharmacologic profile of desloratadine: a review. Allergy. 2001; 56 Suppl 65.:7-13.
Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol. 1990; 30(4):364-371.
KreutnerW, Hey JA,Anthes J, BarnettA,Young S,Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 2000;50(4):345-352.
Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol. 1988; 26(5):497-502.
Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008; 63 Suppl 89:1-20.
Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet. 2004; 43(2):121-129.
Hurst M, Spencer CM. Ebastine: an update of its use in allergic disorders. Drugs. 2000; 59(4):981-1006.
Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J.A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999; 29 Suppl 3:200-5.:200-205.
Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C, Mc Cracken N: Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine in healthy volunteers. Eur J Clin Pharmacol 2001;57:571–582.
Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron. 2001; 89(1):101-104.
Matzke GR, Yeh J, Awni WM, Halstenson CE, Chung M. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy. 1987; 59(6 Pt 2):25-30.
Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007; 63(11):1011-1017.
Sudhakara RM, Dwarakanatha RD, Murthy PS. Rupatadine:pharmacological profile and its use in the treatment of allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2009; 61(4):320-332.
